Oct 31, 2016 Cellectar Biosciences Announces Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma and Other Hematologic Malignancies Learn More
Oct 24, 2016 Cellectar Biosciences Announces Data on CLR 131 Accepted For Poster Presentation at the 58th Annual American Society of Hematology Meeting & Exposition Learn More
Oct 11, 2016 Cellectar Biosciences To Present at SeeThru Equity and Dawson James Investor Conferences Learn More